View Author
patient myeloma expression cluster bortezomib trial treatment neuropathy survival sample analysis study table blood cancer chapter response signature therapy thalidomide factor figure gene expression prognostic j clin oncol phase probe hovon value group dexamethasone protein grade plasma relapse translocation antigen maintenance presence mm patients number pathway month marrow bortezomib-induced testi mirna myeloma cells probe sets dataset classification disease induction relapse cases tumor development outcome result target novel oncol level -65/gmmg frequency cycle hovon -65/gmmg trial classi difference emc -92 signature cta cluster cta genes myeloma patients 10-3 proteasome system activity inhibitor percentage myeloma plasma cells testis-selective
8 Most Recent Publications
|
Molecular profiling in multiple myeloma
(Doctoral Thesis)
Broyl, A. |
2012-11-07
|
|
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: Prognostic markers and potential targets for immunotherapy
(Article)
Duin, M. van Broyl, A. Sahota, S.S. Sonneveld, P. Knegt, Y. de Goldschmidt, H. Richardson, P.G. Hop, W.C.J. Holt, B. van der Joseph-Pietras, D. Mulligan, G. Neuwirth, R. |
2011-11-01
|
|
MicroRNA signatures characterize multiple myeloma patients
(Article)
Corthals, S.L. Sun, S.M. Zweegman, S. Jongen-Lavrencic, M. Sonneveld, P. Kuiper, R. Knegt, Y. de Broyl, A. Holt, B. van der Beverloo, H.B. Peeters, J.K. Jarari, L. Lokhorst, H.M. |
2011-11-01
|
|
Bortezomib-induced peripheral neuropathy: Facts and genes - Authors' reply
(Article)
Broyl, A. Jongen, J.L.M. Sonneveld, P. |
2011-02-01
|
|
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
(Article)
Broyl, A. Corthals, S.L. Durie, M.G. Goldschmidt, H. Sonneveld, P. Jongen, J.L.M. Holt, B. van der Kuiper, R. Knegt, Y. de Duin, M. van Jarari, L. Bertsch, U. Lokhorst, H.M. |
2010-11-01
|
|
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
(Article)
Broyl, A. Hose, D. Lokhorst, H. Knegt, Y. de Peeters, J. Jauch, A. Bertsch, U. Buijs, A. |
2010-10-07
|
|
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
(Article)
Mulligan, G. Mitsiades, C. Trepicchio, W.L. Broyl, A. Sonneveld, P. Shaughnessy, J. Bergsagel, P.L. Schenkein, D. Esseltine, D-L. Boral, A.L. Anderson, K.C. Bryant, B. Zhan, F. Chng, W.J. Roels, S. Koenig, E. Fergus, A. Huang, Y. Richardson, P.G. |
2007-04-15
|
|
Influence of genetic polymorphisms in CYP3A4, CYP3AS, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma
(Article)
Schilthuizen, C. Broyl, A. Holt, B. van der Knegt, Y. de Lokhorst, H.M. Sonneveld, P. |
2007-02-01
|
